ArticleBiochemical and biophysical research communications2004
Prediction of quaternary assembly of SARS coronavirus peplomer.
Article in Biochemical and biophysical research communications, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Molecular dynamics of Middle East Respiratory Syndrome Coronavirus (MERS CoV) fusion heptad repeat trimers.Computational biology and chemistry · 2018Article
- Genomic and evolutionary inferences between American and global strains of porcine epidemic diarrhea virus.Preventive veterinary medicine · 2016Article
- Canine enteric coronaviruses: emerging viral pathogens with distinct recombinant spike proteins.Viruses · 2014Review
- Review
- SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion.Virology · 2009Article
- Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide.Journal of virology · 2009Article
- Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection.Clinical microbiology reviews · 2007Review
- SARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2007Review
- Adaptive evolution of the spike gene of SARS coronavirus: changes in positively selected sites in different epidemic groups.BMC microbiology · 2006Article
- Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus.FEBS letters · 2006Article
- Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy.The Journal of biological chemistry · 2005Article
- Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human.Proceedings of the National Academy of Sciences of the United States of America · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tertiary structures of the S1 and S2 domains of the spike protein of the coronavirus which is responsible of the severe acute respiratory syndrome (SARS) have been recently predicted. Here a molecular assembly of SARS coronavirus peplomer which accounts for the available functional data is suggested. The interaction between S1 and S2 appears to be stabilised by a large hydrophobic network of aromatic side chains present in both domains. This feature results to be common to all coronaviruses, suggesting potential targeting for drugs preventing coronavirus-related infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.